DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: RANEXA

Summary for Tradename: RANEXA

Patents:10
Applicants:1
NDAs:1
Suppliers: see list3
drug
patent expirations by year for
 RANEXA

Pharmacology for Tradename: RANEXA

Drug ClassAnti-anginal

Clinical Trials for: RANEXA

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Status: Completed Condition: End-stage Renal Disease; Cardiovascular Disease

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
Status: Completed Condition: Atrial Fibrillation

Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Status: Completed Condition: Persistent Atrial Fibrillation

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
Status: Completed Condition: Type 2 Diabetes Mellitus

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)
Status: Recruiting Condition: Diabetic Peripheral Neuropathic Pain

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)
Status: Completed Condition: Chronic Angina

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy
Status: Completed Condition: Diabetes Mellitus, Type 2

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Status: Completed Condition: Angina Pectoris; Coronary Artery Disease; Type 2 Diabetes Mellitus

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
Status: Completed Condition: Type 2 Diabetes Mellitus

Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study
Status: Recruiting Condition: Cardiomyopathy; Chest Pain; Dyspnea

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526Feb 12, 2007RXYes6,303,607<disabled><disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526Feb 12, 2007RXYes6,369,062<disabled>YY<disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526Feb 12, 2007RXYes6,479,496<disabled><disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526Feb 12, 2007RXYes6,503,911<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc